This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

JAMA. 2002;287:579.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 2002;50:1159

Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) remains in short supply, and the shortage will continue into mid-2002.¹ Shortages are greatest in the public sector. Despite high vaccination rates, pertussis continues to cause serious illness and death, particularly among infants aged <6 months who are too young to have completed the 3-dose primary series of DTaP. In 2000, a total of 1,873 pertussis cases (rate: 99 per 100,000 infants aged <6 months) and 16 deaths were reported among infants aged <6 months. Vaccinating infants on time with the 3-dose primary series of DTaP to protect them from serious disease remains a priority during this vaccine shortage.

The shortage began in 2000 when two manufacturers (Wyeth Lederle, Pearl River, New York, and Baxter Hyland Immuno Vaccines, Baltimore, Maryland) stopped production of DTaP.¹ Aventis Pasteur (Swiftwater, Pennsylvania) and GlaxoSmithKline (Philadelphia, Pennsylvania), producers of Tripedia® and Infanrix^TM, respectively, . . . [Full Text of this Article]